Outlook Therapeutics® Reports Financial Results for Fiscal

Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024Company reaffirms potential for European approval for...

Related Keywords

Japan ,United States ,China ,United Kingdom ,Russell Trenary ,Jenene Thomas ,Outlook Therapeutics Inc ,European Medicines Agency ,Exchange Commission ,Nasdaq ,Amerisourcebergen ,Drug Administration ,Committee For Medicinal Products Human Use ,Marketing Authorization Application ,License Application ,Chief Executive Officer ,Protocol Assessment ,Regulatory Update ,Outlook Therapeutics ,Medicinal Products ,Human Use ,Syntone Biopharma ,Year Ended September ,Outlook Therapeutic ,Annual Report ,Nasdaq Otlk ,Nc ,